TenQ · fact sheet · filings current to · price as of
DexCom (DXCM)
A mixed picture - strengths and real weaknesses - 25 of 36 checks passed.
Latest close : $87.90, -2.0% on the day; -4.8% from the 52-week high. Refreshed every trading night.
Full analysis: report · all charts. Financial statements are computed from SEC EDGAR XBRL filings, current to . The share price and everything built on it (market cap, multiples, yields, the Value and Trend checks) are refreshed every trading night; this page shows the close of . Not investment advice.
Key figures
| Share price (delayed close) | $87.90 |
| Market cap | $33.2B |
| 52-week range | $54.84 - $92.34 |
| P/E | 35.7x |
| P/E, own 7-year median | 87.9x |
| P/S | 6.7x |
| Free cash flow yield | 4.2% |
| Dividend yield | - |
| Revenue (TTM) | $5.0B |
| Net income (TTM) | $1000M |
| Free cash flow (TTM) | $1.4B |
| Gross margin | 62.5% |
| Operating margin | 22.9% |
| Return on equity | 38.1% |
| Revenue growth (1y) | +15.5% |
| Revenue CAGR (3y) | +17.0% |
| Debt / equity | - |
| Cash & short-term investments | $1.1B |
| Shares outstanding | 377.4m (cover page of the latest filing, 2026-07-23) |
The score: 25 of 36 checks passed
Six chapters, six pass/fail checks each. Five are computed from the filings; Trend is price behaviour, and says so.
Is DXCM stock cheap or expensive right now?
Value · 2 of 6 checks passed. Expensive against its own history and its sector - you're paying up for what you get. chapter →
Is DexCom still growing?
Growth · 5 of 6 checks passed. The business is genuinely growing - revenue +15.5% in the last year, and it's consistent. chapter →
Does DexCom make real money?
Quality · 5 of 6 checks passed. Rare profitability: margins and returns on capital are well above its peers. chapter →
Can DexCom survive a bad year?
Health · 4 of 6 checks passed. Financially sound overall, with one or two things worth watching. chapter →
What does DexCom hand back to shareholders?
Shareholder returns · 4 of 6 checks passed. Cash comes back to owners, with a caveat or two in the checks below. chapter →
Which way is DXCM trending?
Trend analysis · 5 of 6 checks passed. The market agrees: the stock is in a healthy uptrend on every horizon. chapter →
Are insiders buying or selling DXCM?
Open-market buys: $0.00 · sells: $11M, across the recent Form 4 filings. detail →
Other instruments and medical devices we cover: Thermo Fisher Scientific (TMO) · Intuitive Surgical (ISRG) · every company →
Method: figures computed deterministically from SEC EDGAR XBRL (companyfacts, frames, financial-statement-and-notes datasets, Form 4); prices delayed end-of-day. Scores count transparent pass/fail checks. Missing data is shown as missing, never estimated. Last changed . © TenQ - cite with a link to this page.